Investor Presentation Full Year 2017

Investor Presentation Full year 2017 Slide 77 Oral semaglutide reduced HbA1c and body weight in a 26-week phase 2 trial in type 2 diabetes HbA1c reduction from a mean baseline of 7.9% Placebo HbA1c (%) 8.0 Weight loss from a mean base line of 92 kg Sema 20 mg Sema 40 mg Sema 2.5 mg - Sema 5 mg Sema 10 mg Weight loss (kg) 0.0 Sema 1 mg sc 7.5 7.0 6.5 6.0 0.0 0 2 -2.0 -4.0 -6.0 -8.0 6 8 10 12 14 16 18 20 22 24 26 Time (weeks) 0 2 6 10 12 14 16 18 20 22 24 26 Time (weeks) Inclusion criteria: Type 2 diabetes; 7.0% HbA1c 9.5%; treatment with diet and exercise with or without metformin; sc: subcutaneous; sema: semaglutide changing diabetes® novo nordisk

View entire presentation